238 related articles for article (PubMed ID: 32642736)
1. Management of cutaneous neurofibroma: current therapy and future directions.
Chamseddin BH; Le LQ
Neurooncol Adv; 2020 Jul; 2(Suppl 1):i107-i116. PubMed ID: 32642736
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous Neurofibroma Heterogeneity: Factors that Influence Tumor Burden in Neurofibromatosis Type 1.
Jiang C; McKay RM; Lee SY; Romo CG; Blakeley JO; Haniffa M; Serra E; Steensma MR; Largaespada D; Le LQ
J Invest Dermatol; 2023 Aug; 143(8):1369-1377. PubMed ID: 37318402
[TBL] [Abstract][Full Text] [Related]
3. [Treatment and progress of cutaneous neurofibroma].
Zhu B; Wei C; Wang W; Gu B; Li Q; Wang Z
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2022 Sep; 36(9):1064-1071. PubMed ID: 36111466
[TBL] [Abstract][Full Text] [Related]
4. Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1.
Chamseddin BH; Hernandez L; Solorzano D; Vega J; Le LQ
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31038470
[TBL] [Abstract][Full Text] [Related]
5. Spatiotemporal Loss of
Chen Z; Mo J; Brosseau JP; Shipman T; Wang Y; Liao CP; Cooper JM; Allaway RJ; Gosline SJC; Guinney J; Carroll TJ; Le LQ
Cancer Discov; 2019 Jan; 9(1):114-129. PubMed ID: 30348677
[TBL] [Abstract][Full Text] [Related]
6. Activation of PLCγ/AKT/IκBα/p65 signaling increases inflammation in mast cells to promote growth of cutaneous neurofibroma.
Xu J; Zhang H; Li C; Du H; Shu M; Jia J
Life Sci; 2019 Dec; 239():117079. PubMed ID: 31756343
[TBL] [Abstract][Full Text] [Related]
7. Treatment of cutaneous neurofibromas with carbon dioxide laser: Technique and patient experience.
Peltonen S; Jannic A; Wolkenstein P
Eur J Med Genet; 2022 Jan; 65(1):104386. PubMed ID: 34768015
[TBL] [Abstract][Full Text] [Related]
8. Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.
Cannon A; Pichard DC; Wolters PL; Adsit S; Erickson G; Lessing AJ; Li P; Narmore W; Röhl C; Rosser T; Widemann BC; Blakeley JO; Plotkin SR;
Neurology; 2021 Aug; 97(7 Suppl 1):S15-S24. PubMed ID: 34230202
[TBL] [Abstract][Full Text] [Related]
9. A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.
Nguyen HTL; Kohl E; Bade J; Eng SE; Tosevska A; Al Shihabi A; Tebon PJ; Hong JJ; Dry S; Boutros PC; Panossian A; Gosline SJC; Soragni A
Cell Rep Methods; 2024 May; 4(5):100772. PubMed ID: 38744290
[TBL] [Abstract][Full Text] [Related]
10. Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.
Oliveira LB; Geller M; Cunha KS; Santos A; Bernacchi A; Rubenstein AE; Takirambudde S; Mezitis S; de Almeida Ito Brum C; Darrigo LG; Ribeiro MG
Heliyon; 2021 Mar; 7(3):e06518. PubMed ID: 33817379
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive treatment of cutaneous neurofibromas (cNFs): Results of a randomized prospective, direct comparison of four methods.
Richey P; Funk M; Sakamoto F; Plotkin S; Ly I; Jordan J; Muzikansky A; Roberts J; Farinelli W; Levin Y; Garibyan L; Blakeley JO; Anderson RR
J Am Acad Dermatol; 2024 Apr; 90(4):767-774. PubMed ID: 38086517
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous neurofibromas in the genomics era: current understanding and open questions.
Allaway RJ; Gosline SJC; La Rosa S; Knight P; Bakker A; Guinney J; Le LQ
Br J Cancer; 2018 Jun; 118(12):1539-1548. PubMed ID: 29695767
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults.
Fertitta L; Bergqvist C; Armand ML; Moryousef S; Ferkal S; Jannic A; Ravaud P; Tran VT; Ezzedine K; Wolkenstein P
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1359-1366. PubMed ID: 35412677
[TBL] [Abstract][Full Text] [Related]
14. Mast Cells in Human Cutaneous Neurofibromas: Density, Subtypes, and Association with Clinical Features in Neurofibromatosis 1.
Kallionpää RA; Ahramo K; Martikkala E; Fazeli E; Haapaniemi P; Rokka A; Leivo I; Harvima IT; Peltonen J; Peltonen S
Dermatology; 2022; 238(2):329-339. PubMed ID: 34237737
[TBL] [Abstract][Full Text] [Related]
15. Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.
Maguiness S; Berman Y; Rubin N; Dodds M; Plotkin SR; Wong C; Moertel C;
Neurology; 2021 Aug; 97(7 Suppl 1):S25-S31. PubMed ID: 34230204
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Cutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.
Wozniak B; Bove T; Zawada T; Calik J
Case Rep Dermatol; 2023; 15(1):194-201. PubMed ID: 37899948
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of CO2- and Er:YAG laser ablation of multiple cutaneous neurofibromas in von Recklinghausen's disease.
Kriechbaumer LK; Susani M; Kircher SG; Distelmaier K; Happak W
Lasers Med Sci; 2014 May; 29(3):1083-91. PubMed ID: 24189926
[TBL] [Abstract][Full Text] [Related]
18. Global research trends in cutaneous neurofibromas: A bibliometric analysis from 2003 to 2022.
Wang J; Fu J; Zhou Y; Gao D; Qing J; Yang G
Skin Res Technol; 2024 Feb; 30(2):e13595. PubMed ID: 38279591
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous neurofibromas: patients' medical burden, current management and therapeutic expectations: results from an online European patient community survey.
Guiraud M; Bouroubi A; Beauchamp R; Bocquet A; Grégoire JM; Rauly-Lestienne I; Blanco I; Wolkenstein P; Schmitt AM
Orphanet J Rare Dis; 2019 Dec; 14(1):286. PubMed ID: 31801570
[TBL] [Abstract][Full Text] [Related]
20. Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Morphological and Immunohistochemical Study.
Friedrich RE; Nörnberg LKN; Hagel C
Anticancer Res; 2022 Mar; 42(3):1247-1261. PubMed ID: 35220215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
